Published in Vaccine Weekly, June 14th, 2000
The company announced that it plans to continue the trial as an extension study until the scheduled completion of the original trial. The company is taking this action after ECOG performed an unplanned early analysis on a subset of the 880 patients enrolled in the trial.
Although the trial is fully enrolled, the analysis was conducted at a time when only about half of the patients had received the two years of GMK therapy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly